Personalized answers for Hepatocellular Carcinoma patients
Precision oncology solutions for liver cancer
Liver cancer incidence has more than tripled since 1980. It is the fifth most commonly occurring cancer in men and the ninth in women. There were over 840,000 new cases in 2018, with a constant increase of almost a 3% per year since 2000.
In the EU27 in 2018, there were 66,869 new liver cancer cases diagnosed. According to the World Health Organisation, over 47,000 Europeans die of liver cancer each year. It is one of the fastest rising of all types of cancers in Canada, having still a higher incidence in the US with 70,000 cases diagnosed with primary liver cancer adults in 2018. In Central and South America the incidence of liver cancer has experienced a huge growth, with an average of 69,048 new HCC patients every year and 28,341 deaths annually. Incidence is substantially higher in Africa and Asia, in some cases being the most frequent form of cancer.
Hepatocellular carcinoma (HCC) is the primary liver malignancy (3 of 4 total liver cancers are HCC). It is typically diagnosed late in its course, with a 5-year survival rate of only 10%. Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, HCC is one of the fastest growing causes of death among all cancers and the second cause of death by cancer worldwide. In addition to the loss of lives and life quality, it poses a major economic burden on healthcare.
At Ophiomics we are tackling the problems of detecting, selecting the right patient for the right treatment and following up patients during treatment to insure that liver cancer ceases to be one of the major global causes of cancer death in the world.
Ophiomics – Precision Medicine
Pipeline
We are advancing a pipeline of several products at different development stages, from pre-clinical programs to products undergoing clinical validation. We use a common approach and build on a common platform of technologies and proprietary tools.
Our most advanced product is HepatoPredict, a powerful predictive tool supporting clinical decision in hepatocellular carcinoma. HepatoPredict integrates a molecular signature with clinical parameters in a predictive algorithm with high predictive power. HepatoPredict is currently under multi centric-validation retrospective validation and single-centre prospective validation.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 946364 (EIC Accelerator pilot scheme)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 827173. (SME Intrument Phase I – 2019)
Ophiomics – Precision Medicine
Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.
Team
Leadership
José Pereira Leal, PhD
CEO
José Pereira Leal, PhD, is a bioinformatician with close to 20 years professional experience…show more
Dr. José Pereira-Leal has a PhD in Biomedical Sciences from the University of Oporto (Portugal), having performed all the thesis research work at the Imperial College School o Medicine (London, UK) and the Souwestern Medical School at Dallas (Texas, USA). His PhD thesis focused on the biochemistry and bioinformatics of proteins involved in genetic diseases. He was a post doctoral fellow at the EMBL European Bioinformatics Institute and at the Medical Research Council’s Laboratory of Molecular Biology, both in the UK, in the areas of Computational/Systems Biology and Bioinformatics.
After 10 years abroad, he returned to Portugal where he established and coordinated the Computational Genomics Laboratory, supervising post-docs, PhD and MSc students, as well as clinicians, in projects on comparative genomics, medical genomics and data integration. He also coordinated the Bioinformatics Unit of the Instituto Gulbenkian de Ciência, where he helped establishing the European biological data infrastructure ELIXIR, and its national counterpart, the Portuguese biological data infrastructure BioData.pt.
He is a founder and the executive director of Ophiomics, and is committed to translate the latest advances in Genomic and Bioinformatics research to improve clinical practice and patient care.
show less
Joana Cardoso Vaz, PhD
CTO
Joana Cardoso Vaz, PhD, is a specialist in cancer Genomics, with ample experience collaborating with clinicians…show more
Dr. Joana Cardoso Vaz has an MSc in Human Genetics from the School of Medicine of the University of Lisbon (Portugal), and a PhD in Biomedical Sciences from the University of Leiden (Netherlands). During her PhD research she specialised in cancer genomics, with a focus on colo-rectal cancer.
As a post doctoral fellow she worked at the Instituto de Medicina Molecular and at the Instituto Gulbenkian de Ciência using genomics technologies (NGS, microarrays, qPCR) to study mechanism and markers of cancer progression (Breast, Liver and Oesophageal Cancer). Her frequent and abundant interaction with medical doctors from different specialities (oncologist, pathologists, etc.) give her a broad view about real clinical needs, and her experience in cancer genomics enables her to identify analytical solution to those needs .
She is a founder and the Scientific and Technical Director of Ophiomics.
show less
Board of Directors
- José Pereira Leal, PhD
- Joana Cardoso Vaz, PhD
- José Germano de Sousa, MD
Advisory Board
Partnerships
Grupo Germano de Sousa
The Germano de Sousa Group is the largest Portuguese Clinical Pathology Group, with extensive experience in Clinical Pathology, Anatomic Pathology, Genetics and (Onco) Genomics, and an international footprint with multiple African, European, Middle-eastern and South American clients. They bring their >40 year old experience to support the implementation and development of Ophiomics and its product Portfolio.
Genomics and Bioinformatics advancing Precision Medicine
News
Ophiomics @ European Congress of Pathology
Ophiomics attending the European Congress ...
HepatoPredict first clinical validation published in Annals of Surgery
Our paper “A gene expression ...
DNA methylation fingerprint of hepatocellular carcinoma …
As part of our Liquid ...
Genomics and Bioinformatics advancing Precision Medicine
Ophiomics – Precision Medicine
Contacts
Ophiomics Precision Medicine
Postal address (Headquarters): Pólo Tecnológico de Lisboa, Rua Cupertino de Miranda, 9 – Lote 8, 1600-513 – Lisboa
Lab address: Pólo Tecnológico de Lisboa, Rua António Champalimaud, Lote 1 (sala 14), 1600-514 – Lisboa
Tlf.: +351 211 369 829
Email: info@ophiomics.com